Nuvalent LogoNuvalent LogoNuvalent Logo

Targeted Therapiesfor patients with cancer

With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.

molecue shape

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

View our Approach

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

View our Pipeline
molecue shape
An elderly couple enjoying a peaceful day on the beach.
molecue shape

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Meet our Team

Our clinical trials

Learn More
Arros Card Icon
Arros Logo

A Phase 1/2 study of zidesamtinib (NVL-520) in patients with advanced ROS1-positive NSCLC and other solid tumors.

Alakove Card Icon
Alakove Logo

A Phase 1/2 study of neladalkib (NVL-655) in patients with advanced ALK-positive NSCLC and other solid tumors.

Alakazar Card Icon
Alakazar Logo

A Phase 3 study of neladalkib (NVL-655) in patients with TKI-naïve ALK-positive NSCLC.

Heroex Card Icon
Heroex Logo

A Phase 1 study of NVL-330 in patients with advanced HER2-altered NSCLC.

Read the latest news

View All News
  • Nov 04, 2025

    Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

  • Oct 30, 2025

    Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

  • Oct 18, 2025

    Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025